Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
about
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesPriming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafilBortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura.Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.COP9 signalosome controls the degradation of cytosolic misfolded proteins and protects against cardiac proteotoxicity.Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?Current treatment landscape for relapsed and/or refractory multiple myeloma.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload.Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.The proteasome and proteasome inhibitors in multiple myeloma.Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
P2860
Q27026951-287BF635-1923-4C83-AA9C-5E41271F919CQ28084015-1F570320-C3DE-4D94-9AB4-7F4B68C68D9CQ33430998-A1E2EAA2-09CC-440A-AB24-D8B2E86F4671Q33435129-A07DFCDD-8AE1-4D81-B625-798BF01B7D10Q33627312-932829EB-E875-425B-A071-661F112BB269Q34893956-A462893A-50F1-4C6B-8564-17B0A60BC2EAQ36259493-CF52F2E3-24BF-4D3B-B0A7-A24E5B5C6DBBQ36548064-D2390DD5-E033-47C3-B4B4-9A70E2D53227Q38271032-B20DBEB3-20D9-49F2-9AB4-B656E505EDD4Q38807562-8487CDAD-B1E0-43E8-AC1C-9BF0F370A2F6Q40582501-60620C8F-1967-4FBD-A201-A74781098052Q42428235-4510511C-0E57-45D2-A991-BF8CFD56ED4EQ43127820-70E30457-F09F-4376-9E2C-0BB9D7334472Q47339695-2FF68259-3531-4784-B408-674265F8FD24Q47364092-03644F56-ED42-48AB-A8B1-6240DF74124A
P2860
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bortezomib and heart failure: ...... ch Pharmacovigilance database.
@en
type
label
Bortezomib and heart failure: ...... ch Pharmacovigilance database.
@en
prefLabel
Bortezomib and heart failure: ...... ch Pharmacovigilance database.
@en
P2093
P2860
P50
P356
P1476
Bortezomib and heart failure: ...... nch Pharmacovigilance database
@en
P2093
Benjamin Honton
Caroline Rouvellat
Fabien Despas
Jean Louis Montastruc
Nicolas Dumonteil
P2860
P304
P356
10.1111/FCP.12039
P577
2013-06-19T00:00:00Z